Keros Therapeutics vs X4 Pharmaceuticals
Keros Therapeutics is the larger business, with $244m of revenue in fiscal 2025 against $35.1m for X4 Pharmaceuticals (6.9 times as much). Keros Therapeutics grew faster (6769.4% against 1250.5%). Keros Therapeutics kept more of each dollar of sales as profit: a net margin of 35.7% against -225.6%. Keros Therapeutics carries less debt relative to equity (0.0% against 40.3%).
| Latest fiscal year | Keros TherapeuticsKROS, 2025 | X4 PharmaceuticalsXFOR, 2025 |
|---|---|---|
| Revenue | $244m | $35.1m |
| Revenue growth | 6769.4% | 1250.5% |
| Net income | $87.0m | −$79.2m |
| Operating margin | 27.7% | -247.4% |
| Net margin | 35.7% | -225.6% |
| Return on equity | 19.9% | -76.0% |
| Free cash flow | $106m | −$85.6m |
| Cash | $287m | $217m |
| Total debt | $0 | $75.0m |
| Debt to equity | 0.0% | 40.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $375m | — |
| Employees | 78 | 45 |
| Market value | $215m | $308m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 6 buys, 12 sales | 1 buys, 5 sales |